FDA WARNING_LETTER - Simtra BioPharma Solutions - September 26, 2025

The FDA issued a Warning Letter to Simtra BioPharma Solutions following an inspection of its Simtra Deutschland GmbH facility in Halle/Westphalia, Germany, from September 18 to 26, 2025. The letter outlines significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals (21 CFR parts 210 and 211), leading to adulterated drug products under the Federal Food, Drug, and Cosmetic Act. Key issues include a failure to prevent contamination in aseptic processing areas, specifically citing deficiencies in the Water for Injection (WFI) system design with deadlegs and microbial contamination, an inadequate isolator integrity testing program that permitted production after failed tests, and the use of shedding protective equipment materials. Additionally, the firm failed to establish and follow appropriate written procedures to prevent microbiological contamination, evidenced by inadequately validated Vaporized Hydrogen Peroxide (VHP) decontamination cycles with recurrent biological indicator recoveries and inappropriate acceptance criteria. The FDA requires comprehensive assessments and corrective actions, including a complete overhaul of the WFI system, an independent review of cleaning effectiveness, an improved isolator maintenance program, and enhanced VHP validation. Failure to adequately address these issues may result in further regulatory actions, including product import refusal.